Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 178

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Open access
Van Roosbroeck, Katrien, Fanini, Francesca, Setoyama, Tetsuro, Ivan, Cristina, Rodriguez-Aguayo, Cristian, Fuentes-Mattei, Enrique, Xiao, Lianchun, Vannini, Ivan, Redis, Roxana S., D'Abundo, Lucilla, Zhang, Xinna, Nicoloso, Milena S., Rossi, Simona, Gonzalez-Villasana, Vianey, Rupaimoole, Rajesha, Ferracin, Manuela, Morabito, Fortunato, Neri, Antonino, Ruvolo, Peter P., Ruvolo, Vivian R., Pecot, Chad V., Amadori, Dino, Abruzzo, Lynne, Calin, Steliana, Wang, Xuemei, You, M. James, Ferrajoli, Alessandra, Orlowski, Robert, Plunkett, William, Lichtenberg, Tara M., Davuluri, Ramana V., Berindan-Neagoe, Ioana, Negrini, Massimo, Wistuba, Ignacio I., Kantarjian, Hagop M., Sood, Anil K., Lopez-Berestein, Gabriel, Keating, Michael J., Fabbri, Muller, Calin, George A. · 2017 · Clinical Cancer Research

Abstract

Purpose: The oncogenic miR-155 is upregulated in many human cancers, and its expression is increased in more aggressive and therapy-resistant tumors, but the molecular mechanisms underlying miR-155-induced therapy resistance are not fully understood. The main objectives of this study were to determine the role of miR-155 in resistance to chemotherapy and to evaluate anti-miR-155 treatment to chemosensitize tumors. Experimental Design: We performed in vitro studies on cell lines to investigate the role of miR-155 in therapy resistance. To assess the effects of miR-155 inhibition on chemoresistance, we used an in vivo orthotopic lung cancer model of athymic nude mice, which we treated with anti-miR-155 alone or in combination with chemotherapy. To analyze the association of miR-155 expression and the combination of miR-155 and TP53 expression with cancer survival, we studied 956 patients with lung cancer, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. Results: We demonstrate that miR-155 induces resistance to multiple chemotherapeutic agents in vitro, and that downregulation of miR-155 successfully resensitizes tumors to chemotherapy in vivo. We show that anti-miR-155-DOPC can be considered non-toxic in vivo. We further demonstrate that miR-155 and TP53 are linked in a negative feedback mechanism and that a combination of high expression of miR-155 and low expression of TP53 is significantly associated with shorter survival in lung cancer. Conclusions: Our findings support the existence of an miR-155/TP53 feedback loop, which is involved in resistance to chemotherapy and which can be specifically targeted to overcome drug resistance, an important cause of cancer-related death. Clin Cancer Res; 23(11); 2891–904. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-1025

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 178

Metadata

Authors
Van Roosbroeck, K., Fanini, F., Setoyama, T., Ivan, C., Rodriguez-Aguayo, C., Fuentes-Mattei, E., Xiao, L., Vannini, I., Redis, R. S., D'Abundo, L., Zhang, X., Nicoloso, M. S., Rossi, S., Gonzalez-Villasana, V., Rupaimoole, R., Ferracin, M., Morabito, F., Neri, A., Ruvolo, P. P., Ruvolo, V. R., Pecot, C. V., Amadori, D., Abruzzo, L., Calin, S., Wang, X., You, M. J., Ferrajoli, A., Orlowski, R., Plunkett, W., Lichtenberg, T. M., Davuluri, R. V., Berindan-Neagoe, I., Negrini, M., Wistuba, I. I., Kantarjian, H. M., Sood, A. K., Lopez-Berestein, G., Keating, M. J., Fabbri, M., & Calin, G. A.
Venue
Clinical Cancer Research
Published
2017-05-31
Volume
23
Issue
11
Pages
2891-2904
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2559239118
Cited by
178
References
2
FWCI
7.04
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1025
The paper
Van Roosbroeck, K., Fanini, F., Setoyama, T., Ivan, C., Rodriguez-Aguayo, C., Fuentes-Mattei, E., Xiao, L., Vannini, I., Redis, R. S., D'Abundo, L., Zhang, X., Nicoloso, M. S., Rossi, S., Gonzalez-Villasana, V., Rupaimoole, R., Ferracin, M., Morabito, F., Neri, A., Ruvolo, P. P., . . . Calin, G. A. (2017). Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1025

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.